Clindacyl 150 mg Tablets

Country: United Kingdom

Language: English

Source: VMD (Veterinary Medicines Directorate)

Active ingredient:

Clindamycin

Available from:

Vetoquinol UK Ltd

ATC code:

QJ01FF01

INN (International Name):

Clindamycin

Pharmaceutical form:

Tablet

Prescription type:

POM-V - Prescription Only Medicine – Veterinarian

Therapeutic group:

Dogs

Therapeutic area:

Antimicrobial

Authorization status:

Expired

Authorization date:

2002-06-07

Summary of Product characteristics

VÉTOQUINOL (UK) Ltd
CLINDACYL 150 mg
Vm 08007/4103
October 2003
1
1/27/21 10:59 AM
PART II
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
CLINDACYL 150MG TABLETS
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 150mg Clindamycin (as Clindamycin Hydrochloride)
FOR A FULL LIST OF EXCIPIENTS, SEE SECTION 6.1
3.
PHARMACEUTICAL FORM
Tablet.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Clindacyl
150mg
Tablets
are
indicated
for
the
treatment
of
infected
wounds,
abscesses,
superficial
pyoderma
and
oral
cavity/dental
infections
caused
by
or
associated with clindamycin-sensitive staphylococci, streptococci,
bacteroidaceae,
_Fusobacterium necrophorum_, _ Clostridium perfringens_ and
osteomyelitis caused by
_Staphylococcus aureus_. Clindacyl 150mg Tablets can also be used to
help provide
antimicrobial cover during dental procedures.
4.3
CONTRA-INDICATIONS
Do not administer to animals with hypersensitivity to clindamycin and
lincomycin
preparations.
Do not administer to rabbits, guinea pigs, chinchillas, hamsters,
horses or ruminants.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Before use of Clindacyl 150mg tablets, the identification of causative
pathogenic
micro-organisms should be carried out and their susceptibility to
clindamycin should
be established.
Clindamycin and lincomycin show parallel-resistance. There is a
partial cross-
resistance to erythromycin and other macrolide-antibiotics.
VÉTOQUINOL (UK) Ltd
CLINDACYL 150 mg
Vm 08007/4103
October 2003
2
1/27/21 10:59 AM
4.5
SPECIAL PRECAUTIONS FOR USE
(I) SPECIAL PRECAUTIONS FOR USE IN ANIMALS
During prolonged therapy of one month or greater, periodic liver and
kidney function
tests and blood counts should be performed. Patients with severe renal
and/or very
severe hepatic disturbances accompanied by severe metabolic
aberrations should be
dosed with caution and should be monitored by serum examination during
high dose
clindamycin therapy.
(II)
SPECIAL
PRECAUTIONS